DDInter1678 DDInter1435
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Sirolimus {u} (Compound) binds {v} (Gene) ABCB1
Sirolimus {u} (Compound) upregulates {v} (Gene) WDR13
Sirolimus {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Immunologic Activity
Sirolimus {u} (Compound) downregulates {v} (Gene) IMP3
Sirolimus {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lansoprazole
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Sirolimus (Compound) resembles Pimecrolimus (Compound)
Sirolimus (Compound) binds ABCB1 (Gene)
Sirolimus (Compound) upregulates WDR13 (Gene)
Sirolimus (Compound) is included by Decreased Immunologic Activity (Pharmacologic Class)
Sirolimus (Compound) downregulates IMP3 (Gene)
Sirolimus (Compound) causes Aspartate aminotransferase increased (Side Effect)
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib